The Novartis commitment to the Global CML community
The development of the first molecularly targeted therapy for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) epitomizes the commitment of the affiliates of Novartis AG to consistently discovering, developing, and producing broadly available novel therapies that improve the lives of patients with cancer. The same way GLIVEC® (imatinib) transformed first-line treatment of Ph+ CML, TASIGNA® (nilotinib) has the promise to offer even better outcomes for newly diagnosed patients.
The commitment of the affiliates of Novartis AG also extends to offering comprehensive educational and support services to the physicians and patients who use TASIGNA® and GLIVEC®.
Next: Ongoing Clinical Trials in CML
Note: Before prescribing, please read full European Summary of Product Characteristics.
